Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy  by Poillet-Perez, Laura et al.
Redox Biology 4 (2015) 184–192Contents lists available at ScienceDirectRedox Biologyhttp://d
2213-23
Abbre
ATG, au
novirus
GABARA
1; GEC1
hypoxia
shock p
mTORC
mily, py
PINK1,
sequest
n Corr
EA3922
France.
E-mjournal homepage: www.elsevier.com/locate/redoxMini ReviewInterplay between ROS and autophagy in cancer cells, from tumor
initiation to cancer therapy
Laura Poillet-Perez, Gilles Despouy, Régis Delage-Mourroux, Michaël Boyer-Guittaut n
Université de Franche-Comté, Laboratoire de Biochimie, EA3922 «Estrogènes, Expression Génique et Pathologies du Système Nerveux Central», SFR IBCT
FED4234, UFR Sciences et Techniques, 16 Route de Gray, 25030 Besançon Cedex, Francea r t i c l e i n f o
Article history:
Received 7 November 2014
Received in revised form
8 December 2014
Accepted 9 December 2014
Available online 10 December 2014
Keywords:
ROS
Mitochondria
Antioxidant
Mitophagy
Autophagy
Cancerx.doi.org/10.1016/j.redox.2014.12.003
17/& 2014 The Authors. Published by Elsevier
viations: ; 3-MA, 3-methyladenine; AMPK, A
tophagy related gene; ATG8, autophagy relate
E1B 19-kDa-interacting protein 3; EMT, epithe
P, GABAA receptor-associated protein; GABAR
, glandular epithelial cell 1; GABARAPL2, GAB
-inducible factor-1 α; HMGB1, high-mobility
rotein; KEAP1, Kelch-like ECH-associated prot
1, mammalian target of rapamycin complex; N
rin domain containing 3; NRF2, nuclear factor
PTEN induced putative kinase 1; ROS, reactive
osome 1; ULK1, unc-51 like autophagy activat
esponding author: Université de Franche-Com
, SFR IBCT FED4234, UFR-ST, 16 Route de G
ail address: michael.boyer-guittaut@univ-fcoma b s t r a c t
Cancer formation is a complex and highly regulated multi-step process which is highly dependent of its
environment, from the tissue to the patient. This complexity implies the development of speciﬁc
treatments adapted to each type of tumor. The initial step of cancer formation requires the transfor-
mation of a healthy cell to a cancer cell, a process regulated by multiple intracellular and extracellular
stimuli. The further steps, from the anarchic proliferation of cancer cells to form a primary tumor to the
migration of cancer cells to distant organs to form metastasis, are also highly dependent of the tumor
environment but of intracellular molecules and pathways as well. In this review, we will focus on the
regulatory role of reactive oxygen species (ROS) and autophagy levels during the course of cancer de-
velopment, from cellular transformation to the formation of metastasis. These data will allow us to
discuss the potential of this molecule or pathway as putative future therapeutic targets.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Macroautophagy (hereafter called autophagy) is a multi-step
process which maintains cellular homeostasis via the degradation
and recycling of long-lived proteins, intracellular aggregates as
well as damaged organelles. This process requires the intervention
of about 40 proteins and leads to the formation of a double
membrane structure, called the phagophore, which engulfs part of
the cytoplasm as well as organelles, to form an autophagosome.
This vesicle ultimately fuses with the lysosome to induce the for-
mation of an autophagolysosome and the degradation and re-
cycling of its content [1]. The induction of autophagy is regulated
by several kinase cascades but the main regulator of the inductionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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pamycin complex 1 (mTORC1) kinase which can integrate the
different extracellular stresses (for a review, see [2]). Following
inhibition of mTORC1, unc-51 like autophagy activating kinase 1
(ULK1)/ATG1 and phosphatidyl inositol kinase 3 (PI3K) are sub-
sequently activated to induce the initiation of the formation of a
phagophore. The elongation of the double membrane structure is
then activated by two post-translational modiﬁcations, similar to
those described during ubiquitinylation or SUMOylation, leading
to the covalent addition of ATG12 onto ATG5 and ATG8 family
members onto phospholipids. The latter is considered to be cor-
related to the levels of autophagy and therefore to be accepted as a
direct marker of intracellular autophagy.
Autophagy is regulated by numerous stresses such as nutrient
starvation, hypoxia, ATP/AMP ratio, intracellular ROS levels, bac-
teria and virus infection or chemical drugs. This cellular pathway,
ﬁrst believed to be non-speciﬁc, is now divided in basal or induced
autophagy which can be either not selective or selective [3]. The
latter requires cargo adapter proteins, such as Sequestosome 1
(SQSTM1)/p62, neighbor of BRCA1 gene 1 (NBR1) or Bcl-2/ade-
novirus E1B 19-kDa-interacting protein 3 long form (NIX/BNIP3L),
to induce the recruitment of cargos, which are the molecules or
organelles targeted for degradation, into the autophagosomes. This
step also requires an interaction between the cargo adapters and
the ATG8 family proteins (LC3, GABARAP, GABARAPL1/GEC1 and
GABARAPL2) via two domains present within the cargo adapter
proteins: an Ubiquitin Binding domain (UBA) recognizing ubiqui-
tinylated substrates, and a LC3-interaction domain (LIR) re-
cognizing ATG8 proteins [4–7]. Amongst the different types of
selective autophagy, we can cite mitophagy, inducing the de-
gradation of damaged mitochondria, xenophagy, leading to the
degradation of extracellular pathogens, and aggrephagy, allowing
the degradation of intracellular aggregates [8].
Autophagy has been described to be involved in biological
processes such as cellular homeostasis, development and immune
response but it has also been demonstrated to be deregulated in
different pathologies, in particular neurodegenerative diseases or
cancers [9]. If it is now well accepted that autophagy presents a
protective role in neurodegenerative diseases, its effect is far more
complex and paradoxal in cancers. According to the stage of the
tumor as well as the tissue or the cells targeted, the role of au-
tophagy can be positive or negative for the growth of the tumor
[10–12]. For example, autophagy can prevent the transformation
of healthy cells into cancerous cells but can also induce resistance
to chemotherapeutic treatments. More importantly, this positive
or negative effect seems to be directly correlated to autophagy
levels induced by different intracellular or extracellular stressors
such as ROS accumulation.
In this review, we will describe the link between ROS produc-
tion and its effect on autophagy during the different stages of the
formation of a tumor: cellular transformation, tumor growth, in-
teraction between stroma and cancer cells, induction of metastasis
and response to chemical treatments.Relationship between autophagy and ROS
ROS are a group of molecules including superoxide anion
(O2), hydroxyl radical (OH) and hydrogen peroxide (H2O2).
These molecules are synthetized within the cells through oxygen
metabolism and represent, at low levels, important signaling
molecules [13]. Moreover, ROS can also be involved in oxidative
stress which is characterized by elevated intracellular levels of ROS
leading to proteins, lipids and DNA damage [14]. In healthy cells,
mitochondria produce the majority of intracellular ROS through
the leaking of electrons from the electron transport chain duringoxidative phosphorylation [15,16]. Intracellular ROS levels can
then increase the mitochondrial dysfunction inducing the accu-
mulation of high concentration of ROS, oxidization of proteins,
lipids and DNA, redox imbalance and oxidative stress [17,18].
Moreover, ROS can also play an important role in inﬂammation by
inducing the secretion of pro- or anti-inﬂammatory molecules
regulating the different steps of cancer development (for a de-
tailed review, see [19]).
As previously described, ROS levels have been shown to reg-
ulate autophagy induction in the cells. In a speciﬁc manner, in-
duction of autophagy following nutrient starvation requires the
production of H2O2 that oxidizes ATG4, an enzyme involved in
ATG8 protein maturation and delipidation. This oxidization mod-
iﬁcation mainly inactivates the delipidation activity of ATG4
leading to an increased formation of LC3-associated autophago-
somes [20] (Fig. 1(1)). In an indirect manner, ROS can regulate
autophagy through AMP-activated protein kinase (AMPK). Indeed,
oxygen and nutrient deprivation induce AMP:ATP accumulation
and activation of AMPK leading to the inhibition of mTORC1 and to
autophagy induction [21,22]. AMPK also regulates autophagy by
phosphorylating ULK1/ATG1, activation which is necessary to in-
duce autophagy upon starvation [23–25]. AMPK is sensitive to
oxidative stress and can be phosphorylated by the upstream ki-
nase AMPK kinase (AMPKK) following H2O2 accumulation, leading
to its activation and to an indirect induction of autophagy [26]
(Fig. 1(2)). ROS can also regulate autophagy through the regulation
of transcription factor activity such as NF-κB leading to the in-
duction of autophagy gene expression (BECLIN1/ATG6 or SQSTM1/
p62) in cancer cells [27–29].
Autophagy, ROS and tumorigenesis
Recent studies have described a complex role of the autophagy
pathway during tumor initiation. On one hand, autophagy protects
against the production of ROS in the cells and therefore inhibits
their deleterious effect on DNA mutation, which have been ex-
tensively described to induce tumorigenesis, deﬁned as the
transformation of a normal cell into a cancer cell [30,31] (Fig. 2).
Autophagy is then considered as a tumor suppressor mechanism
by mainly preventing ROS accumulation through elimination of
damaged mitochondria which are known to be the major source of
ROS. This selective autophagy, called mitophagy, is mediated by
two different molecular pathways: NIX/BNIP3L and PARKIN
(PARK2)/PTEN induced putative kinase 1 (PINK1) [32–35]. Nix/
BNIP3L interacts with GABARAP and GABARAPL1 at the autopha-
gosome and targets mitochondria for degradation [36,37]. PARKIN/
PINK1 allows the selective degradation of damaged and dysfunc-
tional mitochondria in response to mitochondrial membrane de-
polarization induced by ROS [38] (Fig. 1(4)). It has been previously
shown that elimination of damaged mitochondria by autophagy
leads to decreased ROS production, thereby limiting tumor-pro-
moting effect of ROS [39]. Consequently, autophagy inhibition,
following ATG5 or ATG7 deletion, leads to chronic oxidative stress,
accumulation of damaged mitochondria, tissue damage and in-
ﬂammation which all favor tumor initiation [40–42]. Moreover,
autophagy can regulate oxidative stress through the nuclear factor
erythroid 2-related factor 2 (NRF2)/kelch-like ECH-associated
protein 1 (KEAP1) and SQSTM1/p62 pathway [43,44]. SQSTM1/
p62, an autophagy substrate and cargo adapter, can interact with
and target KEAP1 to the autophagosomes leading to its selective
degradation [45] and the release of NRF2 which can then trans-
locate to the nucleus and activate antioxidant-defense genes, such
as glutathione peroxidase, superoxide dismutase and thioredoxin
[46] (Fig. 1(5)). Upon normal conditions, NRF2 is sequestered by
KEAP1 and inactivated by proteasomal degradation. Following
oxidative stress, either ubiquitin activity of KEAP1 is inhibited or
Fig. 1. Relationship between autophagy and ROS. ROS levels regulate autophagy levels by different pathways such as: (1) oxidization of ATG4 leading to accumulation of
autophagosomes, (2) activation of the AMPK signaling cascade inducing the initiation of autophagy through the ULK1 complex, (3) disruption of BECLIN1–BCL-2 interaction
leading to the initiation of autophagy or (4) alteration of mitochondria homeostasis leading to mitophagy activation. Autophagy inhibits ROS accumulation through (4) the
elimination of damaged mitochondria by mitophagy or (5) the degradation of KEAP1 by selective autophagy mediated by SQSTM1/p62 and the expression of NRF2-regulated
antioxidant genes.
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the inhibition of the degradation of NRF2 and to its activation.
Autophagy also presents a tumor-suppressive role by regulating
chronic inﬂammation which has been described as an important
risk of cancer initiation such as in liver cancer [47,48]. Inﬂammation
is an important process activated by a loss of tissue or cell home-
ostasis which can be induced by tissue damage, cell death or pa-
thogen infection. The activation of inﬂammation leads to the release
of soluble molecules (cytokines, chemokines, ROS, matrix protei-
nases or vascular epithelial growth factor, VEGF) by macrophages
and mast cells in order to activate the recruitment and inﬁltration of
leukocytes at the site of injury. Several studies have shown that
autophagy defects following deletion of ATG16L1, BECLIN1 or LC3B
induce an accumulation of damaged mitochondria and mitochon-
drial ROS leading to an induction of inﬂammation linked to in-
creased levels of IL-1β and IL-18 [49–52]. Indeed, ROS generation
activate pro-inﬂammatory factors such as the NOD-like receptor
family, pyrin domain containing 3 (NLRP3) inﬂammasome [50,52], a
multiprotein complex responsible of maturation and secretion of
these pro-inﬂammatory cytokines. But, IL-1 has also been demon-
strated to be involved in the production of ROS and high levels of IL-
1 have been associated with a poor prognosis [53]. Moreover, au-
tophagy also increases the extracellular release of nuclear protein
high-mobility group box protein 1 (HMGB1) depending of its redox
status [54,55]. The secreted HMGB1 can then be recognized by
different membrane receptors such as toll-like receptors (TLR2,
4 and 9) or macrophage-1 antigen (Mac-1) leading to the accel-
eration of the pro-inﬂammatory response dependent on cytokines
and type-I interferon (IFN) and later to tumor progression as well as
metastasis [56]. Defects of autophagy therefore lead to aninﬂammatory environment which contributes to cancer initiation.
However, the interplay between inﬂammatory cytokines and cancer
remains unclear given the pro- and anti-tumoral effect of these
molecules depending on the tumor context.
During later stages of tumor initiation, autophagy is required
for cell transformation by the RAS oncogene in order to promote
cell tolerance to stress (Fig. 2). Indeed, autophagy inhibition re-
duces transformation, proliferation of mouse embryonic ﬁbro-
blasts (MEF) transformed with HRAS and MDA-MB-231 breast
cancer cells presenting ectopic KRAS expression [57]. In these
models, autophagy is necessary for energy production during
transformation thanks to its role in glucose uptake and glycolytic
ﬂux. Moreover, other studies have shown that immortalized baby
mouse kidney (iBMK), MCF-10A and pancreatic ductal adeno-
carcinoma (PDAC) cell lines described to express oncogenic RAS
present high levels of basal autophagy and that inhibition of au-
tophagy following ATG5 or ATG7 deletion prevent RAS-induced
growth and proliferation [58–60]. This observation could be ex-
plained by the fact that mitochondrial respiration is necessary for
RAS-induced tumorigenesis and that active autophagy is necessary
to maintain cellular homeostasis [61]. Indeed, impairment of au-
tophagy in these different models is associated with decreased cell
survival, accumulation of damage mitochondria and oxidative
stress suggesting that activation of oncogenic RAS induces au-
tophagy to sustain metabolic needs and lead to an “addiction” of
cells to autophagy [58,59,62–64]. Moreover, deﬁciency in SQSTM1/
p62 has been shown to reduce tumorigenicity and increase ROS
levels following RAS activation [58,65,66].
Similar results were obtained in a different model of tumor-
igenesis. Inhibition of autophagy by FAK family-interacting protein
Fig. 2. Autophagy, ROS and cancer. The role of autophagy in cancer depends on the tissue, the stage and the type of tumor. During the early steps of cancer development,
autophagy plays a protective role by preventing ROS-induced damages on DNA and protein leading to an inhibition of tumorigenesis. During the late steps of cancer
development (promotion, progression and metastasis), autophagy presents a pro-tumoral role through the elimination of ROS-induced metabolic stress and the production
of nutrients required for cancer cell survival. During the development of the primary tumor, a strong interaction between stroma cells of the microenvironment and cancer
cells has been observed. The cancer cells under hypoxia induce the formation of ROS which can activate autophagy in stroma cells. These cells will then provide high-energic
nutrients, such as lactate or ketones, necessary for cancer cell survival and proliferation.
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driven by the polyoma virus middle T (PyMT) oncogene leads to
decreased tumor initiation and progression associated with an
increased number of mitochondria presenting an abnormal mor-
phology [67], conﬁrming the pro-tumorigenic role of autophagy.
Taken together, these studies conﬁrm the complex and para-
doxal role of autophagy in cancer initiation. Indeed, autophagy can
act as a tumor suppressive mechanism during early stages of
cancer development through the prevention of inﬂammation and
genome instability [41,42] but can also induce cancer cell survival
during transformation-induced metabolic stress [68,69].
Autophagy, ROS, tumor progression and metastasis
During in vivo tumor formation, autophagy has been shown to
be necessary for the cancer cells to survive under hypoxic stress
before the vascularization of the tumor [30]. Even if the mechan-
ism is still unclear, many studies suggest a role of autophagy in the
regulation of cancer cell metabolism allowing them to meet re-
quirements for rapid proliferation.
High levels of autophagy are indeed observed in hypoxic re-
gions of tumors and autophagy has been described to be activated
by hypoxia (lack of adequate oxygen supply) and ischemia (glu-
cose deprivation and hypoxia) to promote survival of cancer cells
[41,42,64] (Fig. 2). Hypoxia induces ROS production leading to the
stabilization of hypoxia-inducible factor-1α (HIF-1α) [70]. HIF-1α,
a key regulator of oxygen homeostasis, induces mitophagy
through expression of Bcl-2/adenovirus E1B 19-kDa-interacting
protein 3 (BNIP3) allowing the cells to survive during prolonged
hypoxia by preventing increased levels of ROS [71]. Indeed, BNIP3
is an HIF-1α target gene and disrupts the interaction betweenBECLIN1/ATG6 and BCL-2, inducing its release and autophagy in-
duction [72] (Fig. 1(3)). Disruption of autophagy by BECLIN1, ATG5
or ATG7 knockdown leads to hypoxia-induced cell death. BNIP3-
induced autophagy is necessary to prevent the increase in ROS
production during hypoxia [73] and therefore represents a survival
adaptive mechanism [69,74]. Autophagy can also be induced, in-
dependently of HIF-1α, by different pathways such as AMPK and
Unfolded Protein Response (UPR) during hypoxia [75,76]. More-
over, cancer cells require higher bioenergetic needs than normal
cells leading to a reprograming of metabolism. This includes the
recycling of intracellular components to increase the production of
ATP and tricarboxylic acid (TCA) cycle intermediates which in re-
turn leads to accumulation of ROS due to increased oxidative
phosphorylation [10,77,78].
Tumor progression and aggressiveness are characterized by
metastasis, epithelial–mesenchymal transition (EMT) and angio-
genesis. Metastasis is a multi-step process which allows cancer
cells to migrate to distant organ sites [79,80]. EMT is the ﬁrst step
of metastasis and is characterized by the loss of epithelial prop-
erties as well as the acquirement of mesenchymal properties
leading to increased cell mobility [81]. Previous studies have de-
scribed a pro-metastasis role of autophagy (Fig. 2). For example,
inhibition of autophagy by FIP200 deletion leads to a decrease in
metastatic potential associated with an accumulation of damaged
mitochondria which could lead to increased level of ROS [67].
Moreover, increased autophagy in human cancer is associated
with metastasis and poor prognosis for patients with melanoma
and breast cancer [82,83]. Interestingly, autophagy also promotes
resistance to anoikis (detachment-induced cell death) and inva-
sion [84,85], two processes necessary for colonization of other
organs. Indeed, detachment of cells from the primary tumor
L. Poillet-Perez et al. / Redox Biology 4 (2015) 184–192188induces autophagy which in return provides resistance to anoikis
[57,86,87] which is necessary for the metastasis of hepatocellular
carcinoma (HCC) and mammary epithelial cells (MEC) [88,89].
During detachment from the extracellular matrix (ECM), epithelial
cells present modiﬁcations of their metabolism, including a re-
duction of ATP production and increased ROS production [90],
which will lead to AMPK-induced autophagy in response to me-
tabolic stress [23] or to protein kinase like endoplasmic reticulum
kinase (PERK)-induced autophagy in response to oxidative stress
[91]. Inhibition of autophagy by knock-down of ATG12 or deﬁ-
ciency in SQSTM1/p62 also leads to a decrease in invasion and
migration phenotypes correlated with metabolism defects in
glioma and glioblastoma cells [92,93]. Similarly, autophagy in-
creases HCC invasion abilities through activation of EMT [94].
Moreover, inhibition of autophagy in pancreatic ductal adeno-
carcinoma (PDAC) leads to tumor regression of xenografts and
orthotopic models and mice prolonged survival [59].
However, the role of autophagy in metastasis is still a double-
edged sword [95] and autophagy can also inhibit autophagy in-
dependently of ROS. Autophagy can inhibit metastasis by activat-
ing the release of HMGB1 which induces an anti-tumor immune
response [95]. Autophagy may also regulate metastasis by in-
hibiting tumor necrosis and immune cell inﬁltration necessary for
this metastasis [64,96,97]. Similarly, autophagy can inhibit EMT by
degrading SNAIL and TWIST, two major regulators of this process,
leading to decreased EMT and invasion phenotypes [98]. We can
hypothesize that autophagy might also inhibit EMT through
elimination of ROS and inhibition of inﬂammation. In fact, EMT can
be induced by IL-1, IL-6 or TGFβ cytokines which regulate SNAIL or
TWIST. ROS can also induce HIF-1α and lysil oxidase (LOX) ex-
pression leading to decreased levels of E-Cadherin associated with
an activation of EMT and cancer cell migration [99].
Angiogenesis is a key step during tumor growth and metastasis
[100] but the relationship between angiogenesis and autophagy is
poorly understood. Indeed, several studies have shown that an-
giogenesis inhibitors induce autophagy and apoptosis in en-
dothelial cells, independently of nutrient or hypoxia stresses
[101,102]. On the contrary, treatment of human aortic endothelial
cells (HAEC) with chemerin, an angiogenesis stimulator, increases
ROS production in association with an upregulation of autophagy
genes [103].
Angiogenesis has also been described to be regulated by in-
ﬂammation. Indeed, hypoxic cancer cells present elevated levels of
HIF-1α which lead to the expression of angiogenic factors such as
VEGF which can also be released by activated immune cells (e.g.
macrophages) during inﬂammation. Therefore, autophagy would
allow cell survival under hypoxia and starvation in the tumor core
while inﬂammation would lead to the induction of angiogenesis,
two processes regulated by ROS accumulation.
Autophagy, ROS and stroma–tumor relationship
Tumor stroma is a compartment which includes different cell
types such as myoﬁbroblasts/cancer-associated ﬁbroblasts (CAFs),
immune cells, endothelial and adipocyte cells. These cells are in
constant interaction with tumor cells and can regulate tumor cell
proliferation, tumor growth, progression and metastasis [104].
Tumor stroma is characterized by the presence of different stress
factor such as hypoxia, high level of ROS, high metabolic stress and
lack of growth factors which can induce autophagy in several tu-
mor compartments and especially in CAFs [105–110]. Recent stu-
dies highlighted a discrepancy in the autophagic activities be-
tween tumor and stroma cells and a model called "the autophagic
tumor stroma model of cancer metabolism” has been proposed by
the authors [111–115] (Fig. 2). In this model, cancer cells can in-
duce an oxidative stress mimicking hypoxia in CAFs and thereforeincreasing ROS production. This stress activates the transcription
factors HIF-1α and NF-κB leading to the induction of autophagy
and mitophagy in the microenvironment surrounding the tumor.
The increase of autophagy in tumor stroma allows cells to survive
against senescence and induce the secretion of recycled and high-
energetic nutrients, such as ketone and lactate, which will feed
cancer cells during tumor growth and metastasis [116–119].
Moreover, ROS production in ﬁbroblasts increases DNA damage,
genomic instability and stemness in cancer cells, mechanisms es-
sential for tumor progression.
Therefore, contrary to the initial “Warburg effect” dogma de-
scribing that cancer cells rely mainly on glycolysis during tumor
growth, cancer cells are now described to present a decreased
autophagy ﬂux, a high oxidative phosphorylation and a high ROS
production. On the other hand, while the stroma cells rely on a
high autophagic activity which is believed to recycle the nutrients
necessary in order to ‘feed’ the adjacent proliferating cancer cells.
This model has been conﬁrmed by a genome wide transcriptional
analysis which demonstrated that more than 95 mitochondria-
associated genes were up-regulated in human breast cancer cells
[120]. Among these genes, 40 were involved in mitochondrial
translation of proteins of the oxidative phosphorylation chain.
More interestingly, these genes were not expressed, or only at very
low levels, in the adjacent stroma cells and some of these markers
were associated with a poor clinical outcome. The authors con-
clude that the tumor cells should be seen as a “parasite under-
going anabolic reprogramming to accentuate its mitochondrial
power”.
These two models can be combined to describe the oxidative
phosphorylation active/non-autophagic cancer cells to be ‘fed’ in
nutrients by the glycolytic/autophagic stroma cells.
Autophagy, ROS and cancer therapy
According to the recent paradigm, autophagy has been shown
to be induced by and to protect against cellular stress induced by
numerous drugs used in cancer treatment. These observations led
to the development of several clinical trials involving the addition
of an inhibitor of the autophagy ﬂux, such as hydroxychloroquine,
together with a drug already in use in cancer treatment in order to
potentiate its effect (for a review, see [121]). More interestingly,
various anti-cancer treatments have been shown to activate ROS-
induced autophagy which in turn leads to either the development
of cell drug resistance or to the induction of apoptosis or both.
Regarding the complexity of cellular effects observed during can-
cer therapy, several models have been proposed, each involving an
important role of ROS as well as autophagy or apoptosis. The ﬁrst
model describes the use of anticancer drugs inducing the accu-
mulation of ROS leading to cell death. Nevertheless, the accumu-
lation of ROS also increased cytoprotective autophagy levels
leading to cancer cell drug resistance and cancer cell survival. In
this particular case, the use of autophagy inhibitors restored the
sensitivity to the treatment (Fig. 3(1)). One example is the use of
Ciclopiroxolamine (CPX) in human rhabdomyosarcoma (Rh30 and
RD) cells which induces ROS-induced cytoprotective autophagy.
The authors demonstrated the activation of the Mitogen-activated
protein kinases (MAPKs), extracellular signal-regulated kinases 1/2
(ERK1/2), c-Jun N-terminal kinase (JNK) and p38 MAP kinase (p38
MAPK) signaling cascade by CPX and ROS but only JNK has been
shown to be directly involved in autophagy induction [122]. In the
second model, Honokiol, a drug currently in development for the
treatment of prostate cancer, induces autophagy in vitro and in
tumors in mice models inducing cell drug resistance. The inhibi-
tion of drug-induced autophagy by 3-methyladenine (3-MA)or
ATG5 siRNA led to increased cancer cell death via apoptosis [123]
(Fig. 3(2)). Moreover, the authors showed that the use of
Fig. 3. Interplay between ROS and autophagy in the regulation of therapy efﬁciency. Anti-cancer treatments can increase ROS-induced autophagy leading to cell drug
resistance (1–3). Given these observations, inhibitors of autophagy (1–3) or antioxidants (2) might be used to potentiate or restore the cytotoxicity effect of the drug.
Regarding the fourth model, ROS accumulation induces cytotoxic autophagy and apoptosis therefore the use of autophagy inhibitors or antioxidants would inhibit the effect
of the drug (4). These four models, involving ROS, autophagy and apoptosis, point out the difﬁculty to ﬁnd the most relevant combination of autophagy inhibitors or
antioxidants together with anti-cancer drugs in cancer therapy and the necessity to ﬁrst characterize and understand the cancer cell response to cancer therapies.
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their models inhibits autophagy levels demonstrating the direct
involvement of ROS in the induction of autophagy. This model can
also explain the effects observed with drugs targeting mitochon-
dria, such as Mitoquinone in MDA-MB-231 cells [124] or Quercetin
in human glioblastoma cells (U373MG) [125]. The alteration of
mitochondria homeostasis would increase ROS levels but also ac-
tivate autophagy, the latter leading to cell survival by degrading
damaged mitochondria. Inhibiting autophagy levels, by 3-MA,
chloroquine or ATG7 knockdown, will restore the effect of the
compound through induction of ROS-induced apoptosis. A third
model has been described for the use of 3-bromopyruvate (3BrPA),
an inhibitor of hexokinase II involved in glycolysis, in breast cancer
cells (MDA-MB-231) or artemisinin, an anti-malaria drug, in hu-
man lung cancer cells (A549). The authors proposed that increased
ROS-induced apoptosis was the consequence of the combined
treatment of 3BrPA and chloroquine and that ROS accumulation
was not the cause of the induction of autophagy [126] (Fig. 3(3)).
In this model, the addition of autophagy inhibitors together with
the anticancer drug would increase cell death but an antioxidant
would not. A fourth model has been described in breast cancer cell
lines using carnosol, a polyphenol, which induced early ROS-in-
duced autophagy and late apoptosis leading to cell death [127].
The authors showed that autophagy and cell death were correlated
to mitochondrial damage as well as increased ROS levels. In this
model, the authors demonstrated the tight link between autop-
hagy and apoptosis and that autophagy inhibitors and anti-
oxidants would inhibit cancer cell death (Fig. 1(4)). Similar datawere obtained with psoralidin or Resveratrol which increased ROS
accumulation and autophagy levels leading to human lung cancer
(A549) and human colon cancer (HT-29, COLO 201) cell death,
respectively. These effects were blocked by the addition of 3-MA
or antioxidants [128,129].
Altogether, these studies highlight the complexity of choosing
the right treatment for a speciﬁc patient or a speciﬁc tumor. This
observation led researchers to adapt their protocols to the genetic
or biochemical background of each patient, a procedure called
theranostics or personalized medicine. This approach is based on
the development of new diagnostic protocols, targeting new spe-
ciﬁc biomarkers, whose results would lead to the use of a speciﬁc
targeted therapy. In regards of the interplay of ROS and autophagy,
the ﬁrst difﬁculty will be to ﬁnd easy and rapid protocols to
quantify both ROS and autophagy levels in cellulo, in situ and
in vivo. Regarding ROS levels, some protocols have already been set
up to quantify in vivo levels. We can cite the use of ﬂuorescent
probes regulated by ROS such as Dichloroﬂuorescein diacetate
(DCF-DA), Dihydrorhodamine 123 (DHR) or Amplex Ultrared, a
highly speciﬁc ﬂuorogenic substrate used to detect H2O2 in human
skeletal muscle [130,131], or the use of spin probes, modiﬁed by
ROS, and detected in human tissues by Electron Paramagnetic
Resonance (EPR) [132]. A second protocol would consist of the
detection of biological molecules modiﬁed in vivo by ROS and then
considered as biomarkers. For example, we can cite the
15-F2t-IsoP(8-Iso-PGF2α) which gives a major urinary metabolite
(2,3-Dinor-5,6-Dihydro-15-F2t-IsoP(F2-IsoP-M)) following oxidiza-
tion [133]. A third, but indirect possibility would be to quantify
L. Poillet-Perez et al. / Redox Biology 4 (2015) 184–192190mitochondrial activity, which is described as a major cause of ROS
accumulation in tissues, by using ﬂuorescent probes. For example,
18F-ﬂuorobenzyl triphenylphosphonium cation (18F-FBnTP) has
been used as a PET (Positron emission tomography) imaging probe
to quantify mitochondrial membrane potential defects in vivo in
breast or prostate cancers [134]. The major problem will be to
accurately quantify autophagy levels in cancer and stroma cells.
Indeed, LC3B levels have been described as an accurate marker of
the number of autophagosomes in cells but we also know that an
accumulation of these intracellular vesicles can be linked to an
increase of autophagy induction or an inhibition of autophago-
some degradation by the lysosomes. To our knowledge, no other
autophagy marker is currently available in order to discriminate
between an increase or a decrease of overall autophagy ﬂux in vivo
[135]. Therefore, before using the pair autophagy/ROS as new
cancer biomarkers to choose the adequate therapy protocol, re-
search will have to develop new diagnostic tests to quantify these
markers in vivo.Conclusions
In this review, we summarized the current data showing the
involvement of ROS signaling and autophagy during the course of
cancer initiation, progression as well as response to cancer therapy
but more importantly, we pointed out the complex interplay be-
tween these two cellular signal and mechanism. Taken together,
these data particularly demonstrate that the effects of ROS and
autophagy are different according to the stage of the development
of the tumor. Precautions will have to be taken before considering
the choice of a particular treatment since we showed that, ac-
cording to the drug used, ROS or autophagy can favor or inhibit the
applied treatment. Therefore a potential new way of cancer
treatment might be to include antioxidants or autophagy in-
hibitors to inhibit cytoprotective ROS-induced autophagy during
the course of treatment. But, in some cases, adding antioxidants or
autophagy inhibitors might also decrease ROS or autophagy-in-
duced cell death. It is therefore now clear that, in the future, in
order to choose the more efﬁcient combination of drugs for each
treatment, an extensive knowledge of the cellular events occurring
in each particular tumor category (tissue, cells, stage, autophagy
levels, ROS levels) would be necessary to tightly regulate the
balance between ROS accumulation and ROS-induced autophagy
or apoptosis and induce cancer cell death and tumor regression
in vivo. The future of cancer treatment will require the develop-
ment of personalized medicine, called theranostic, and the de-
velopment of ‘one speciﬁc treatment for one speciﬁc tumor in one
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